CAMBRIDGE, Mass., Dec. 13 /CNW/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from a planned interim safety analysis from PROVE 1, an ongoing Phase 2b clinical trial of the investigational
hepatitis C virus (HCV) protease inhibitor telaprevir (VX-950):
